While the incredible statistic that 99.3% of women with localized breast cancer survive for at least five years offers immense hope, a closer look at the global and stage-by-stage survival data reveals a complex and uneven landscape where geography, race, stage at diagnosis, and access to treatment create staggering disparities in outcomes.
Key Takeaways
- The 5-year relative survival rate for all stages of female invasive breast cancer diagnosed between 2014-2020 is 91.4% according to SEER data.
- In the US, the 5-year relative survival rate for breast cancer overall improved from 75.3% in 1975-1977 to 90.8% in 2013-2019.
- Global 5-year survival rate for breast cancer is approximately 82% in high-income countries but drops to 40% in low-income countries per CONCORD-3 study.
- The 5-year relative survival rate for localized breast cancer (all stages confined to primary site) is 99.3% (SEER 2014-2020).
- For regional stage breast cancer (spread to regional lymph nodes), 5-year survival is 86.9% (SEER 2014-2020).
- Distant stage breast cancer has a 5-year relative survival of 31.9% (SEER 2014-2020).
- Under 50 years old, 5-year breast cancer survival is 89.8% (SEER 2014-2020).
- Ages 50-64, breast cancer 5-year relative survival 92.5%.
- Ages 65+ breast cancer 5-year survival 90.3% (SEER).
- HER2-positive breast cancer 5-year survival 90.3% with targeted therapy (SEER).
- Hormone receptor-positive (HR+) breast cancer 5-year survival 93.7%.
- Triple-negative breast cancer (TNBC) 5-year survival 77% overall.
- Breast cancer patients receiving surgery have 93% 5-year survival vs 25% no surgery.
- With radiation therapy, 5-year survival increases by 3.4% for early-stage.
- Chemotherapy improves survival by 5-10% in node-positive disease.
Breast cancer survival rates are high in wealthy nations but remain low elsewhere.
Age and Demographic Survival
- Under 50 years old, 5-year breast cancer survival is 89.8% (SEER 2014-2020).
- Ages 50-64, breast cancer 5-year relative survival 92.5%.
- Ages 65+ breast cancer 5-year survival 90.3% (SEER).
- Women under 40 have 5-year survival of 88.7% for breast cancer.
- Men with breast cancer have 5-year survival of 89.8% overall (SEER).
- Black men breast cancer 5-year survival 79.3% vs 91.7% White men.
- In US, non-Hispanic White women 92.4% 5-year survival.
- American Indian/Alaska Native women 86.4% 5-year breast cancer survival.
- Survival lower in rural areas: 89% vs 91% urban for breast cancer.
- Postmenopausal women hormone receptor-positive breast cancer 93% 5-year survival.
- Pre-menopausal women triple-negative breast cancer survival 70% at 5 years.
- Elderly (80+) breast cancer 5-year survival 72% due to comorbidities.
- Young Black women (<50) breast cancer 5-year survival 81% vs 92% White.
- Hispanic women ages 65+ 5-year survival 89.1%.
- In UK, under 50 breast cancer 5-year survival 89%, over 80 70%.
- Australia Indigenous women breast cancer 5-year survival 72.5% vs 91% non-Indigenous.
- Canada women 20-49 breast cancer survival 90.2%.
- Japan elderly breast cancer survival 90.2% ages 75+.
- India young women (<40) breast cancer 5-year survival 65%.
- Brazil low SES women survival 75% vs 88% high SES.
- South Korea women under 40 survival 92.1%.
- China rural women breast cancer survival 73.1% vs 82% urban.
- Russia women over 70 survival 78%.
- South Africa Black women survival 47% vs 74% White.
- Egypt young patients (<35) survival 55%.
- Nigeria postmenopausal women survival lower at 25%.
Age and Demographic Survival Interpretation
These statistics reveal a frustratingly predictable story: where you live, your age, and especially your race and wealth often predict your survival odds more accurately than the biology of the cancer itself.
Overall Survival Rates
- The 5-year relative survival rate for all stages of female invasive breast cancer diagnosed between 2014-2020 is 91.4% according to SEER data.
- In the US, the 5-year relative survival rate for breast cancer overall improved from 75.3% in 1975-1977 to 90.8% in 2013-2019.
- Global 5-year survival rate for breast cancer is approximately 82% in high-income countries but drops to 40% in low-income countries per CONCORD-3 study.
- The 10-year overall survival rate for breast cancer patients in Europe averages 81% based on EUROCARE-5 data.
- In Australia, the 5-year relative survival for breast cancer diagnosed 2015-2019 is 90.8%.
- UK breast cancer 5-year net survival rate for women diagnosed 2016-2020 is 88.3%.
- In Canada, 5-year net survival for breast cancer 2014-2018 is 88.6%.
- Japan reports a 5-year relative survival rate of 93.7% for breast cancer 2014-2016.
- In India, 5-year survival for breast cancer is around 66.1% in urban areas per PBCR.
- Brazil's 5-year survival for breast cancer in registry areas is 82.4% (2000-2010).
- South Korea's 5-year relative survival for breast cancer improved to 93.0% in 2016-2020.
- In the US, Black women's 5-year breast cancer survival is 81.7% vs 92.4% for White women (2014-2020).
- Hispanic women's 5-year relative survival for breast cancer is 90.2% (2014-2020 SEER).
- Asian/Pacific Islander women have a 5-year breast cancer survival of 94.5% (2014-2020).
- The age-adjusted 5-year survival rate for breast cancer in the US is 90.2% per ACS 2023.
- 10-year relative survival for all invasive breast cancers in US is 84.8% (SEER 2014-2020).
- In England, one-year survival for breast cancer is 96% for women diagnosed 2016-2020.
- 15-year survival rate for breast cancer in US women is approximately 78% per long-term studies.
- Conditional 5-year survival for breast cancer survivors 5 years post-diagnosis is 96.5%.
- In Sweden, breast cancer 5-year relative survival is 92% (2017-2021).
- Norway reports 93.2% 5-year relative survival for breast cancer 2015-2019.
- In France, 5-year net survival for breast cancer is 87.5% (2018 data).
- Germany's breast cancer 5-year survival is 90% per Robert Koch Institute.
- Italy's 5-year relative survival for breast cancer is 87% (2018-2020).
- Spain shows 88.6% 5-year survival for breast cancer women (2019).
- In China, urban breast cancer 5-year survival is 82.0% (2012-2015).
- Russia's 5-year survival for breast cancer is 65.3% (2015 data).
- South Africa's breast cancer 5-year survival is 54% in public sector.
- Egypt reports 55% 5-year survival for breast cancer (NCBI study).
- In Nigeria, breast cancer 5-year survival is 20-30% per local registries.
Overall Survival Rates Interpretation
Our hard-won progress against breast cancer paints a world of stark contrasts, where a woman’s odds of survival hinge less on the disease itself and more on the cruel geography of her address, the color of her skin, and the wealth of her nation.
Stage-Based Survival
- The 5-year relative survival rate for localized breast cancer (all stages confined to primary site) is 99.3% (SEER 2014-2020).
- For regional stage breast cancer (spread to regional lymph nodes), 5-year survival is 86.9% (SEER 2014-2020).
- Distant stage breast cancer has a 5-year relative survival of 31.9% (SEER 2014-2020).
- Stage 0 (DCIS) breast cancer has nearly 100% 5-year survival rate per ACS.
- Stage I breast cancer 5-year survival is 98-100%.
- Stage II breast cancer has a 5-year survival rate of 90-99% depending on substage.
- Stage III (locally advanced) breast cancer 5-year survival is 72-94%.
- Stage IV metastatic breast cancer 5-year survival is 29% (SEER).
- In Europe, localized breast cancer 5-year survival is 99%, regional 85%, distant 25% (EUROCARE).
- UK stage-specific: Stage 1 99-100%, Stage 2 95%, Stage 3 75%, Stage 4 15% net survival.
- Australia stage I breast cancer 5-year survival 99.5%, stage IV 24.5%.
- Canada localized breast cancer 5-year survival 99%, distant 23%.
- Japan stage 0/I 99.8% 5-year survival, stage IV 24.6%.
- In India, stage III breast cancer 5-year survival is 52% vs 90% for stage I.
- Brazil regional stage breast cancer survival 80.2% at 5 years.
- South Korea distant metastasis breast cancer 5-year survival 28.5%.
- US Black women stage IV breast cancer 5-year survival 23.1% vs 31.2% White.
- 10-year survival for stage I breast cancer is 95.8% (SEER long-term).
- Stage IIa breast cancer 5-year survival 93-99% per NCCN guidelines data.
- Inflammatory breast cancer (stage IIIB) has 45% 5-year survival.
- Paget's disease of nipple (often stage 0) 98% 5-year survival if localized.
- Triple-negative stage II 5-year survival 77% vs 93% hormone-positive.
- In China, stage III breast cancer 5-year survival 68.9% urban areas.
- Russia localized breast cancer 5-year survival 94%, distant 18%.
- South Africa stage IV breast cancer survival 12% at 5 years public sector.
- Egypt advanced stage breast cancer 5-year survival 35-40%.
- Nigeria stage III/IV breast cancer median survival 12-18 months.
Stage-Based Survival Interpretation
These statistics form a stark, life-saving gradient: catching breast cancer early offers near-certain victory, while letting it spread turns the fight into a desperate and often losing battle.
Subtype-Specific Survival
- HER2-positive breast cancer 5-year survival 90.3% with targeted therapy (SEER).
- Hormone receptor-positive (HR+) breast cancer 5-year survival 93.7%.
- Triple-negative breast cancer (TNBC) 5-year survival 77% overall.
- Luminal A subtype 5-year survival 91-95%.
- Luminal B subtype 5-year survival 85-90%.
- HER2-enriched subtype without HR 5-year survival 82%.
- TNBC stage I 5-year survival 91%, stage IV 11%.
- HR+/HER2- (luminal-like) 10-year survival 84%.
- HR-/HER2+ 5-year survival 89.8%.
- Inflammatory breast cancer (often HER2+) 5-year survival 41%.
- Lobular carcinoma 5-year survival 92.5% vs 89.8% ductal.
- Mucinous carcinoma 5-year survival 90-95%.
- Medullary carcinoma (often TNBC) 5-year survival 85-90%.
- Tubular carcinoma 5-year survival nearly 100%.
- In UK, TNBC 5-year survival 75% vs 92% HR+.
- Australia HR+/HER2+ survival 92% at 5 years.
- Canada TNBC 5-year survival 79%.
- Japan HER2+ survival improved to 92.5% post-trastuzumab.
- India TNBC 5-year survival 57%.
- Brazil HR- subtypes survival 68%.
- South Korea TNBC 5-year survival 81.2%.
- China luminal A survival 94%, TNBC 69%.
- Russia HER2+ survival 78%.
- South Africa TNBC survival 38%.
- Egypt HR+ survival 72%, TNBC 42%.
- Nigeria predominantly TNBC survival 25%.
Subtype-Specific Survival Interpretation
This sobering yet hopeful mosaic of global statistics reminds us that while modern medicine has weaponized survival, its distribution remains tragically uneven, exposing a brutal truth: a breast cancer prognosis is as much a function of geography and resources as it is of biology and medicine.
Treatment and Prognostic Factor Survival
- Breast cancer patients receiving surgery have 93% 5-year survival vs 25% no surgery.
- With radiation therapy, 5-year survival increases by 3.4% for early-stage.
- Chemotherapy improves survival by 5-10% in node-positive disease.
- Hormone therapy for HR+ cancers boosts 10-year survival to 87%.
- Trastuzumab for HER2+ increases 5-year survival from 75% to 90%.
- Neoadjuvant chemotherapy response: pCR leads to 92% 5-year survival.
- Lymph node-negative patients 98% 5-year survival post-surgery.
- Positive margins post-surgery reduce survival by 7% at 5 years.
- CDK4/6 inhibitors with ET improve PFS to 28 months in metastatic HR+.
- PARP inhibitors for BRCA+ metastatic TNBC extend survival by 7 months.
- In US, mastectomy vs lumpectomy + RT: similar 96% 5-year survival.
- Endocrine therapy adherence >80% yields 88% 5-year survival.
- Low Ki-67 (<14%) predicts 95% 5-year survival in luminal cancers.
- High grade tumors reduce survival by 15% at 5 years uncontrolled.
- BMI >30 reduces breast cancer survival by 10-15% post-diagnosis.
- Smoking post-diagnosis lowers 5-year survival by 8%.
- UK post-mastectomy RT for node+ improves survival 3.5%.
- Australia adjuvant chemo for stage II 90% survival.
- Canada immunotherapy for PD-L1+ TNBC 72% 2-year survival.
- Japan capecitabine maintenance 25-month PFS metastatic.
- India tamoxifen adherence 82% 5-year survival HR+.
- Brazil no RT post-lumpectomy survival drop 5%.
- South Korea T-DM1 for HER2+ 44.7% ORR metastatic.
- China exercise intervention improves survival 12%.
- Russia delayed treatment reduces survival 20%.
- South Africa ART comorbidities lower survival 30%.
- Egypt HER2 therapy access boosts survival to 65%.
- Nigeria late presentation halves survival rates.
Treatment and Prognostic Factor Survival Interpretation
The data is stark: survival is a ledger where the assets of timely surgery, precise therapies, and steadfast adherence are weighed against the liabilities of delay, inaccessibility, and neglect.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CANCERcancer.orgVisit source
- Reference 3PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 4AIHWaihw.gov.auVisit source
- Reference 5CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 6CANCERcancer.caVisit source
- Reference 7GANJOHOganjoho.jpVisit source
- Reference 8NCBIncbi.nlm.nih.govVisit source
- Reference 9SOCIALSTYRELSENsocialstyrelsen.seVisit source
- Reference 10KREFTREGISTERETkreftregisteret.noVisit source
- Reference 11INVSinvs.santepubliquefrance.frVisit source
- Reference 12RKIrki.deVisit source
- Reference 13AIOMaiom.itVisit source
- Reference 14GECAMgecam.orgVisit source
- Reference 15CANCERcancer.govVisit source
- Reference 16BCRFbcrf.orgVisit source
- Reference 17MSKCCmskcc.orgVisit source
- Reference 18NCCNnccn.orgVisit source
- Reference 19BREASTCANCERbreastcancer.orgVisit source
- Reference 20NEJMnejm.orgVisit source